EUVIMEDEUVIMED entdecken
Crossref

Metabolic Mechanism of Qizhi Capsule for Treating Hyperlipoidemia Based on Chinmedomics Strategy

Heng Fang iD, Guangli Yan, Le Yang, Ling Kong, Ye Sun, Hui Sun, Biwei Bai iD, YingHan, Hongwei Song, Xijun Wang

Biomedical Chromatography · 2025

DOI: 10.1002/bmc.70192 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biomedical Chromatography, 2025. Verfasst von Heng Fang und 9 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Integration and Innovation of Classic Formula and Modern Chinese medicine, National Chinmedomics Research Center, National TC…. Hauptthemen laut MEDLINE: Drugs, Chinese Herbal, Hyperlipidemias, Metabolomics, Hypolipidemic Agents. Die Arbeit nennt 33 Literaturangaben. Gefördert von: National Natural Science Foundation of China, QiZhi, University Nursing Program for Young Scholars with Creative Talents in Heilongjiang Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

To elucidate the active ingredients, and mechanism of action of Qizhi Capsules (QZC), a traditional Chinese patent medicine for the treatment of hyperlipidemia (HP). A high‐fat diet‐induced HP rat model was used to evaluate the therapeutic effect of QZC. Then, we integrated metabolomics, serum pharmacochemistry, network pharmacology, and molecular docking strategies for investigation. Results showed that QZC significantly alleviated the physiological symptoms of HP, with remarkable restoration of the levels of cholesterol, triglycerides, low‐density lipoprotein, and high‐density lipoprotein. It can also reverse pathological changes in liver function to healthy levels. Besides, metabolomic analysis identified 24 metabolites as biomarkers which are highly related to HP. All the markers were settled back to normal with the intervention of QZC. Seventy‐seven compounds originated from QZC were found in blood; 17 of them were highly related to the trajectory change of biomarkers of HP. These compounds were the potential effective constituents related to its clinical efficacy, such as Emodin et al. These ingredients regulated the biomarker farnesol to target Farnesoid X receptor (FXR) involved in cholesterol and triglyceride metabolism with HP. QZC possesses a favorable efficacy on HP; the core mechanism may activate FXR by modulating farnesol with multiple components, thereby reversing the metabolism of HP.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drugs, Chinese HerbalHyperlipidemiasMetabolomicsHypolipidemic AgentsAnimalsRatsDisease Models, AnimalCholesterolTriglyceridesLipoproteins, LDLLipoproteins, HDLDiet, High-FatNetwork PharmacologyMolecular Docking SimulationLiverBiomarkersFarnesolReceptors, Cytoplasmic and NuclearMaleRats, Sprague-DawleyReceptor, Farnesoid X-Activated

Stichwörter der Autor:innen

ChinmedomicsFarnesoid X receptorQizhi capsulefarnesolhyperlipoidemiaintegration analysis

Substanzen

Drugs, Chinese HerbalCholesterolTriglyceridesLipoproteins, LDLLipoproteins, HDLBiomarkersFarnesolReceptors, Cytoplasmic and NuclearHypolipidemic AgentsReceptor, Farnesoid X-Activated

Autor:innen und Institutionen

  • State Key Laboratory of Integration and Innovation of Classic Formula and Modern Chinese medicine, National Chinmedomics Research Center, National TCM Key Laboratory of Serum Pharmacochemistry, Metabolomics Laboratory,…
  • State Key Laboratory of Dampness Syndrome, The Second Affiliated Hospital Guangzhou University of Chinese Medicine, Guangzhou, China.
  • State Key Laboratory of Quality Research in Chinese Medicine, Macau University of Science and Technology, AvenidaWai Long, Taipa, Macau.

ORCID-Profile: Heng Fang, Biwei Bai

Förderung

  • National Natural Science Foundation of China
  • QiZhi
  • University Nursing Program for Young Scholars with Creative Talents in Heilongjiang Province
  • Heilongjiang Touyan Innovation Team Program

Zitieren

APA

Fang, H., Yan, G., Yang, L., Kong, L., Sun, Y., Sun, H., Bai, B., YingHan, Song, H., & Wang, X. (2025). Metabolic Mechanism of Qizhi Capsule for Treating Hyperlipoidemia Based on Chinmedomics Strategy. Biomedical Chromatography. https://doi.org/10.1002/bmc.70192

Vancouver

Fang H, Yan G, Yang L, Kong L, Sun Y, Sun H, et al. Metabolic Mechanism of Qizhi Capsule for Treating Hyperlipoidemia Based on Chinmedomics Strategy. Biomedical Chromatography. 2025. doi:10.1002/bmc.70192

BibTeX
@article{Fang2025,
  author = {Fang, Heng and Yan, Guangli and Yang, Le and Kong, Ling and Sun, Ye and Sun, Hui and Bai, Biwei and YingHan and Song, Hongwei and Wang, Xijun},
  title = {Metabolic Mechanism of Qizhi Capsule for Treating Hyperlipoidemia Based on Chinmedomics Strategy},
  journal = {Biomedical Chromatography},
  year = {2025},
  doi = {10.1002/bmc.70192}
}
Kostenlos starten →